COHERUS BIOSCIENCES INC (CHRS)
US19249H1032 - Common Stock
Taking everything into account, CHRS scores 2 out of 10 in our fundamental rating. CHRS was compared to 561 industry peers in the Biotechnology industry. CHRS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CHRS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CHRS has reported negative net income.
CHRS had a negative operating cash flow in the past year.
In multiple years CHRS reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: CHRS reported negative operating cash flow in multiple years.
1.2 Ratios
CHRS has a Return On Assets of -0.09%. This is amongst the best in the industry. CHRS outperforms 92.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.09% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-46.91%
ROA(5y)-20.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CHRS has a better Gross Margin (44.71%) than 77.12% of its industry peers.
In the last couple of years the Gross Margin of CHRS has declined.
The Profit Margin and Operating Margin are not available for CHRS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-25.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
CHRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
CHRS has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CHRS has been increased compared to 5 years ago.
CHRS has a better debt/assets ratio than last year.
2.2 Solvency
CHRS has an Altman-Z score of -4.04. This is a bad value and indicates that CHRS is not financially healthy and even has some risk of bankruptcy.
CHRS has a Altman-Z score (-4.04) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.04 |
ROIC/WACCN/A
WACC8.99%
2.3 Liquidity
A Current Ratio of 1.25 indicates that CHRS should not have too much problems paying its short term obligations.
CHRS has a Current ratio of 1.25. This is amonst the worse of the industry: CHRS underperforms 83.96% of its industry peers.
A Quick Ratio of 1.09 indicates that CHRS should not have too much problems paying its short term obligations.
CHRS has a worse Quick ratio (1.09) than 84.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.09 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.50% over the past year.
CHRS shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.17%.
CHRS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.53% yearly.
EPS 1Y (TTM)45.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.3%
Revenue 1Y (TTM)44.17%
Revenue growth 3Y-18.53%
Revenue growth 5YN/A
Sales Q2Q%-5.09%
3.2 Future
CHRS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.13% yearly.
The Revenue is expected to grow by 6.80% on average over the next years.
EPS Next Y56.76%
EPS Next 2Y33.65%
EPS Next 3Y22.58%
EPS Next 5Y17.13%
Revenue Next Year-1.51%
Revenue Next 2Y-5.67%
Revenue Next 3Y3.17%
Revenue Next 5Y6.8%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CHRS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CHRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CHRS's earnings are expected to grow with 22.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.65%
EPS Next 3Y22.58%
5. Dividend
5.1 Amount
CHRS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
COHERUS BIOSCIENCES INC
NASDAQ:CHRS (1/8/2025, 8:00:00 PM)
After market: 1.5289 +0.02 (+1.25%)1.51
-0.06 (-3.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.73%
Inst Owner Change0%
Ins Owners1.25%
Ins Owner Change-0.01%
Market Cap173.97M
Analysts81.43
Price Target8.67 (474.17%)
Short Float %28.1%
Short Ratio5.44
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.66%
Min EPS beat(2)52.67%
Max EPS beat(2)92.65%
EPS beat(4)2
Avg EPS beat(4)-73.62%
Min EPS beat(4)-410.06%
Max EPS beat(4)92.65%
EPS beat(8)5
Avg EPS beat(8)-33.29%
EPS beat(12)7
Avg EPS beat(12)-32.89%
EPS beat(16)7
Avg EPS beat(16)-44.69%
Revenue beat(2)2
Avg Revenue beat(2)10.48%
Min Revenue beat(2)3.81%
Max Revenue beat(2)17.15%
Revenue beat(4)2
Avg Revenue beat(4)2.05%
Min Revenue beat(4)-6.92%
Max Revenue beat(4)17.15%
Revenue beat(8)3
Avg Revenue beat(8)-5.34%
Revenue beat(12)3
Avg Revenue beat(12)-8.32%
Revenue beat(16)3
Avg Revenue beat(16)-8.44%
PT rev (1m)-4.8%
PT rev (3m)-10.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-215.91%
EPS NY rev (1m)-49.59%
EPS NY rev (3m)11.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-34.21%
Revenue NY rev (1m)0.82%
Revenue NY rev (3m)-2.58%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.57 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.09
EYN/A
EPS(NY)-0.43
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.54
OCFYN/A
SpS2.64
BVpS-0.76
TBVpS-1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.09% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 44.71% | ||
| FCFM | N/A |
ROA(3y)-46.91%
ROA(5y)-20.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-25.43%
GM growth 5YN/A
F-Score3
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.25 | ||
| Quick Ratio | 1.09 | ||
| Altman-Z | -4.04 |
F-Score3
WACC8.99%
ROIC/WACCN/A
Cap/Depr(3y)32.91%
Cap/Depr(5y)80.31%
Cap/Sales(3y)0.49%
Cap/Sales(5y)0.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.3%
EPS Next Y56.76%
EPS Next 2Y33.65%
EPS Next 3Y22.58%
EPS Next 5Y17.13%
Revenue 1Y (TTM)44.17%
Revenue growth 3Y-18.53%
Revenue growth 5YN/A
Sales Q2Q%-5.09%
Revenue Next Year-1.51%
Revenue Next 2Y-5.67%
Revenue Next 3Y3.17%
Revenue Next 5Y6.8%
EBIT growth 1Y29.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.29%
EBIT Next 3Y32.33%
EBIT Next 5Y18.1%
FCF growth 1Y68.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.94%
OCF growth 3YN/A
OCF growth 5YN/A